12:00 AM
 | 
Jan 30, 2012
 |  BC Week In Review  |  Company News  |  Deals

Illumina, Roche deal

Roche began an unsolicited tender offer to acquire sequencing and microarray company Illumina for $44.50 per share, or about $5.7 billion in cash. The offer will expire at midnight EST on Feb. 24. The price is an 18% premium to Illumina's close of $37.69 on Jan. 24, before the offer was announced. Roche added that the offer is a 64% premium to Illumina's close of $27.17 on Dec. 21, before rumors surfaced of a potential takeout. Roche approached Illumina privately...

Read the full 378 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >